<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">        <PMID Version="1">30397402</PMID>        <DateRevised>            <Year>2018</Year>            <Month>11</Month>            <Day>06</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Print">1661-3791</ISSN>                <JournalIssue CitedMedium="Print">                    <Volume>4</Volume>                    <Issue>5</Issue>                    <PubDate>                        <Year>2009</Year>                        <Month>Nov</Month>                    </PubDate>                </JournalIssue>                <Title>Breast care (Basel, Switzerland)</Title>                <ISOAbbreviation>Breast Care (Basel)</ISOAbbreviation>            </Journal>            <ArticleTitle>A Clinicopathological Evaluation of Male Patients with Breast Cancer.</ArticleTitle>            <Pagination>                <MedlinePgn>308-314</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1159/000230912</ELocationID>            <Abstract>                <AbstractText Label="Background" NlmCategory="UNASSIGNED">Although male breast cancer constitutes only 1% of all breast cancers, its incidence is increasing and it is becoming an important public health issue. The present study aims to present the clinicopathological characteristics of surgically treated male breast cancer patients from multiple centers.</AbstractText>                <AbstractText Label="Patients and Methods" NlmCategory="UNASSIGNED">Twenty-one male patients operated on for breast cancer were retrospectively examined in terms of clinical presentation, pathological characteristics, TNM staging status, and type of surgical treatment.</AbstractText>                <AbstractText Label="Results" NlmCategory="UNASSIGNED">The mean age of the 21 patients was 62.3 years (range 38-94), with the majority being in the range of 50-69 years (61.9%). The most frequent finding was breast mass (85.7%). Most patients underwent modified radical mastectomy (76.1%), and the most prevalent histological type was invasive ductal carcinoma (85.7%). The majority of patients had stage II or III disease, and estrogen receptors were positive in 18 (85.7%) of the patients.</AbstractText>                <AbstractText Label="Conclusion" NlmCategory="UNASSIGNED">Since male breast cancer is a rare condition, it is challenging to conduct prospective randomized trials. Currently, there is a lack of comprehensive data on the diagnosis and management of this condition. Thus, further studies and the implementation of specific guidelines or protocols for this subgroup of patients will aid better management.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Ilhan</LastName>                    <ForeName>Enver</ForeName>                    <Initials>E</Initials>                    <AffiliationInfo>                        <Affiliation>Department of General Surgery, Izmir Bozyaka Education and Research Hospital, Turkey.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Bati</LastName>                    <ForeName>Bakir</ForeName>                    <Initials>B</Initials>                    <AffiliationInfo>                        <Affiliation>Department of General Surgery, Istanbul Okmeydani Education and Research Hospital, Turkey.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Alemdar</LastName>                    <ForeName>Ali</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Department of General Surgery, Istanbul Okmeydani Education and Research Hospital, Turkey.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Coskun</LastName>                    <ForeName>Ali</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Department of General Surgery, Izmir Bozyaka Education and Research Hospital, Turkey.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Sezgin</LastName>                    <ForeName>Arsenal</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pathology, Izmir Bozyaka Education and Research Hospital, Turkey.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Yildirim</LastName>                    <ForeName>Mehmet</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Department of General Surgery, Izmir Bozyaka Education and Research Hospital, Turkey.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Engin</LastName>                    <ForeName>Omer</ForeName>                    <Initials>O</Initials>                    <AffiliationInfo>                        <Affiliation>Department of General Surgery, Izmir Bozyaka Education and Research Hospital, Turkey.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Purten</LastName>                    <ForeName>Mete</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Department of General Surgery, Izmir Bozyaka Education and Research Hospital, Turkey.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2009</Year>                <Month>10</Month>                <Day>01</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>Switzerland</Country>            <MedlineTA>Breast Care (Basel)</MedlineTA>            <NlmUniqueID>101254060</NlmUniqueID>            <ISSNLinking>1661-3791</ISSNLinking>        </MedlineJournalInfo>        <OtherAbstract Type="Publisher" Language="por">            <AbstractText Label="Hintergrund" NlmCategory="UNASSIGNED">Obwohl der Brustkrebs des Mannes nur 1% aller Mammakarzinome ausmacht, ist die Inzidenz doch steigend, und die Erkrankung entwickelt sich zu einem für das Gesundheitswesen bedeutenden Problem. Ziel der vorliegenden Studie ist es, die klinisch-pathologischen Charakteristika chirurgisch behandelter männlicher Brustkrebspatienten verschiedener Zentren darzustellen.</AbstractText>            <AbstractText Label="Patienten und Methoden" NlmCategory="UNASSIGNED">Insgesamt wurden 21 chirurgisch behandelte Brustkrebspatienten retrospektiv bezüglich ihrer klinischen Präsentation, pathologischen Charakteristika, TNM-Status und Art der chirurgischen Behandlung ausgewertet.</AbstractText>            <AbstractText Label="Ergebnisse" NlmCategory="UNASSIGNED">Das mittlere Alter der 21 Patienten war 62,3 Jahre (Spanne 38–94); die Mehrzahl der Patienten war 50–69 Jahre alt (61,9%). Der häufigste Befund war Brusttumor (85,7%). Bei den meisten Patienten wurde eine modifizierte, radikale Mastektomie durchgeführt (76,1%), und der häufigste histologische Befund war invasives duktales Karzinom (85,7%). Die Mehrzahl der Patienten war im Stadium II oder III. 18 (85,7%) Patienten waren östrogenrezeptorpositiv.</AbstractText>            <AbstractText Label="Schlussfolgerung" NlmCategory="UNASSIGNED">Da der Brustkrebs des Mannes eine seltene Erkrankung ist, ist es schwierig, prospektive randomisierte Studien durchzuführen, und im Moment mangelt es an umfassenden Daten zu Diagnose und Management. Weitere Studien sowie die Implementierung spezifischer Richtlinien oder Protokolle für diese Patientenuntergruppe würden deshalb das Management dieser Erkrankung erleichtern.</AbstractText>        </OtherAbstract>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Breast cancer</Keyword>            <Keyword MajorTopicYN="N">Male breast cancer</Keyword>            <Keyword MajorTopicYN="N">Neoplasm</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>11</Month>                <Day>7</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2009</Year>                <Month>11</Month>                <Day>1</Day>                <Hour>0</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2009</Year>                <Month>11</Month>                <Day>1</Day>                <Hour>0</Hour>                <Minute>1</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30397402</ArticleId>            <ArticleId IdType="doi">10.1159/000230912</ArticleId>            <ArticleId IdType="pii">brc-0004-0308</ArticleId>            <ArticleId IdType="pmc">PMC6206969</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>